
|Videos|December 21, 2022
Importance of Biomarker Testing in Patients with NSCLC
Author(s)Mark Socinski, MD, Joshua K. Sabari, MD
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
5



































